Literature DB >> 10651799

Formation of sarcoglycan complex with differentiation in cultured myocytes.

S Noguchi1, E Wakabayashi, M Imamura, M Yoshida, E Ozawa.   

Abstract

The sarcoglycan complex consists of four transmembrane protein subunits. Mutation of any one of the genes encoding these four subunits causes complete loss or marked decrease in expression of the whole complex, resulting in the phenotype of Duchenne-like autosomal recessive muscular dystrophy, termed sarcoglycanopathy. As the basis for understanding this process, we examined how the sarcoglycan complex is formed and associates with other proteins during myogenic differentiation, using a myogenic cell line. Accumulation of the sarcoglycan subunits and formation of the sarcoglycan complex were accomplished with myotube formation. In protein transport inhibition experiments with blefeldin A, we found that the sarcoglycan complex is formed in the endoplasmic reticulum and then associates with the dystroglycan complex and sarcospan en route from the Golgi apparatus to the cell surface. In early myotubes, limited kinds of incomplete sarcoglycan complexes were observed. Their analyses would provide information on the possible patterns of formation of the sarcoglycan complex.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651799     DOI: 10.1046/j.1432-1327.2000.00998.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  13 in total

Review 1.  Finding the sweet spot: assembly and glycosylation of the dystrophin-associated glycoprotein complex.

Authors:  Dewayne Townsend
Journal:  Anat Rec (Hoboken)       Date:  2014-09       Impact factor: 2.064

2.  Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development.

Authors:  Michael S Rafii; Hiroki Hagiwara; Mary Lynn Mercado; Neung S Seo; Tianshun Xu; Tracey Dugan; Rick T Owens; Magnus Hook; David J McQuillan; Marian F Young; Justin R Fallon
Journal:  J Cell Physiol       Date:  2006-11       Impact factor: 6.384

Review 3.  The Dystrophin Complex: Structure, Function, and Implications for Therapy.

Authors:  Quan Q Gao; Elizabeth M McNally
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

4.  Inhibition of proteasome activity promotes the correct localization of disease-causing alpha-sarcoglycan mutants in HEK-293 cells constitutively expressing beta-, gamma-, and delta-sarcoglycan.

Authors:  Stefano Gastaldello; Simona D'Angelo; Susanna Franzoso; Marina Fanin; Corrado Angelini; Romeo Betto; Dorianna Sandonà
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

5.  LG4-5 domains of laminin-211 binds alpha-dystroglycan to allow myotube attachment and prevent anoikis.

Authors:  Jesus Munoz; Yanwen Zhou; Harry W Jarrett
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

6.  Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping.

Authors:  Quan Q Gao; Eugene Wyatt; Jeff A Goldstein; Peter LoPresti; Lisa M Castillo; Alec Gazda; Natalie Petrossian; Judy U Earley; Michele Hadhazy; David Y Barefield; Alexis R Demonbreun; Carsten Bönnemann; Matthew Wolf; Elizabeth M McNally
Journal:  J Clin Invest       Date:  2015-10-12       Impact factor: 14.808

7.  Characterization of the ATP-hydrolysing activity of alpha-sarcoglycan.

Authors:  Dorianna Sandonà; Stefano Gastaldello; Tiziana Martinello; Romeo Betto
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

Review 8.  Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era.

Authors:  Eijiro Ozawa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

9.  Unveiling the degradative route of the V247M α-sarcoglycan mutant responsible for LGMD-2D.

Authors:  Elisa Bianchini; Marina Fanin; Kamel Mamchaoui; Romeo Betto; Dorianna Sandonà
Journal:  Hum Mol Genet       Date:  2014-02-23       Impact factor: 6.150

Review 10.  Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects.

Authors:  Dorianna Sandonà; Romeo Betto
Journal:  Expert Rev Mol Med       Date:  2009-09-28       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.